Cyclerion TherapeuticsKRSA
Recorded

Cyclerion Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration21 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Narration

All right. Good afternoon, everybody, and welcome to the Jefferies 2026 Global Healthcare Conference. It is my pleasure to introduce you now to Jonathan Violin, who is the CEO of Korsana Biosciences. Thank you. Thank you, and thanks to the Jefferies team for having us here today, and thank you for everyone in the room and listening by webcast.

Jonathan ViolinCEO

It's a pleasure to share a bit about Korsana Biosciences with you today. I will be giving some forward-looking statements, so please see our SEC disclosures for more information. To provide an introduction to Korsana, we are founded by Fairmount and Venrock, and led by an experienced team with a track record of building very successful companies. Our lead program, which I'll spend most of today's time talking about, is KRSA-028, which is a next-generation CNS-shuttled anti-amyloid antibody that we've designed to be what we think could be a best-in-class therapeutic for Alzheimer's disease. This molecule is purpose-built from scratch, combining clinically validated biology and engineering technologies that we think reduce risk and aid differentiation in our efforts to deliver a best-in-class clinical profile.

Jonathan ViolinCEO

We are very well-funded. We've just debuted on the public markets, Nasdaq, this September, when we closed our reverse merger and concurrent PIPE. At the end of the third quarter, we reported over $450 million that funds the company into 2029 and through some of the clinical catalysts that I will talk about today. We founded the company two years ago now, based on four key beliefs. First, that Alzheimer's disease is a vast and yet de-risked opportunity. We have two disease-modifying therapies now on the market that prove the biology, that prove that clearing amyloid plaque can slow cognitive decline in this disease, but they are just scratching the surface in terms of market penetration, also in terms of the therapeutic profile that we think can be achieved.

Jonathan ViolinCEO

Secondly, we believe that shuttling, aiding the penetration into the brain of these molecules, is the way to maximize their therapeutic profile, and I'll describe why we believe that. Thirdly, as I mentioned, we think we have a potentially best-in-class profile, that we've designed KRSA-028 to deliver all that can be achieved by clearing amyloid plaques from Alzheimer's disease patient brains. Finally, we have a rapid path to value creation. At least in early clinical development for Alzheimer's, there are now clinically validated biomarkers that allow us to deliver clinical proof of concept and to de-risk our differentiated profile very quickly. I'll start with a review of trontinemab.

Jonathan ViolinCEO

This is Roche's program, which was the first CNS-shuttled anti-amyloid program, which took gantenerumab, an anti-amyloid IgG, turned it into a bispecific by appending a sequence that binds to the transferrin receptor, and just by turning it into a bispecific and engaging the transferrin receptor, dramatically improved the therapeutic profile. Here is some of Roche's data shown here. On the left, looking at CSF to serum ratios of trontinemab compared to gantenerumab. What this shows us is that this shuttling capacity, the binding to the transferrin receptor to shuttle the molecule across the blood-brain barrier, increases CNS exposure by about eightfold, so dramatic improvement. What that delivered in the clinic is shown first on the right, looking at clearance of amyloid plaque. This is the clearing one of the key pathophysiologic signs of Alzheimer's disease.

Jonathan ViolinCEO

Compared to gantenerumab, which the dotted gray lines are the phase III trial results from gantenerumab, we see that trontinemab, at a much lower dose, clears amyloid plaque much faster and deeper than gantenerumab. Perhaps not surprising, given that we delivered a lot more drug in the brain, that you can do the job with a much lower dose. This is the fastest and deepest plaque clearance that has been reported to date, and truly an exciting finding for the field. In addition to faster and deeper plaque clearance, we see a substantially reduced rate of ARIA, amyloid-related imaging abnormalities, which are one of the hallmarks of this class of antibodies that are characterized by microedema, microhemorrhage, usually asymptomatic, sometimes symptomatic, can be quite severe, and occur in rates of 20%-25% in the approved products, shown in gray, lecanemab and donanemab.

Jonathan ViolinCEO

Gantenerumab itself showed both forms of ARIA at a rate of about 25% in its phase III trials. Once turned into a brain shuttle in the context of trontinemab, despite seeing much faster and deeper plaque clearance, the rates of ARIA are dramatically reduced, now looking at single-digit percentage. In this patient population, you expect a rate of a couple percent, even in placebo-treated patients. Very nearly solved the ARIA problem by virtue of shuttling this molecule into the CNS. This is a great step forward. Trontinemab is now in phase III. Roche has completed enrollment, and we are expecting the GUIDED 2 top-line data for their phase III results in the first half of 2028. We think it is a great step forward and congratulate the Roche team for some fantastic work. However, we think this is not the end of the road.

Jonathan ViolinCEO

There is more yet to do to optimize this class of therapeutics. When we think about the profile of trontinemab, first shown here, efficacy, as I mentioned, remarkably fast and deep plaque clearance. We will see in their phase III trial if that leads to stronger efficacy, a greater magnitude of clinical benefit than the approved products. Whatever the bar is that trontinemab sets, we want to explore if we can beat that bar. However, we do not know if that is possible. We may have reached the limit, the ceiling of what is achievable with plaque clearance. Really, the goal is to at least match the efficacy of trontinemab. However, in terms of safety and tolerability and convenience, we think we can do better, starting with safety, shown in the middle panel here.

Jonathan ViolinCEO

Trontinemab was associated with a 10% or 20% rate of anemia in their phase I/II study, and a modest reduction in mean hemoglobin, which is shown on the graph here. This isn't a severe anemia finding. We think the trade-off of lower ARIA for this modest rate of anemia is well worth it. Still, we'd rather avoid the anemia risk if we can. Finally, and perhaps most importantly, trontinemab is dosed intravenously once a month, and it has a very high rate of infusion-related reactions, such that in their phase III program, all patients were pre-treated with corticosteroids. We'd love to deliver a drug that is subcutaneous, well-tolerated locally as well as systemically, and avoids the need for steroid pre-treatment. There's room to improve on the category here. This slide shows in cartoon format how we designed KRSA-028 to deliver on that promise.

Jonathan ViolinCEO

The cartoon illustrates KRSA-028 as a 2+1 bispecific, so it's an IgG backbone that targets amyloid. That's how we deliver efficacy. Appended to the Fc region, we have an antibody fragment that binds to the transferrin receptor. The way we've designed the features of this molecule are in text that I'll go through now, and I'll show data supporting each of these statements on the subsequent slides. Start on the upper left. We designed KRSA-028 to bind to pyroglutamate-modified forms of amyloid. Pyroglutamate is a post-translational modification. It makes amyloid sticky, and so it is enriched in plaques. You can think of this as plaque-enriched or plaque-targeting, similar to donanemab and remternetug from Lilly, which are also targeting pyroglutamate forms of amyloid.

Jonathan ViolinCEO

On the upper right, in collaboration with our partners at Paragon Therapeutics, we designed KRSA-028 to have promising biophysical characteristics and tested it very early in discovery to ensure that we could formulate at a high concentration with low viscosity and adequate stability that we can formulate this for subcutaneous development. On the bottom right, the shuttling moiety that we designed, while it's a novel sequence, was designed to recapitulate the pharmacology of the trontinemab shuttle, because we wanted to be able to connect the dots to the proven mechanism of these CNS-shuttled. The shuttling technology has been 20 or 30 years in the making, and we're standing now on the shoulders of many, many efforts to make this technology work. We wanted to stick with what we know works best, and that, in the case of Alzheimer's disease, is the pharmacology of the trontinemab shuttle.

Jonathan ViolinCEO

It's not just that we bind to the transferrin receptor, we also bind the same epitope as trontinemab, and the affinity is very nearly identical, because we know all three of those matter for the therapeutic profile target, epitope, and affinity. Where the differentiation, much of the differentiation comes from is in proprietary Fc engineering in the stem of the IgG backbone. Here, we wanted to achieve three things. First, we wanted to improve the pharmacokinetics. We did that by extending half-life, not per se to increase efficacy, but instead to allow us to achieve the same exposure as trontinemab with a lower dose. This will help us get to the lowest volume and least frequent dosing, the most benign and convenient product presentation we can. Secondly, we wanted to preserve phagocytosis. That's the mechanism by which the approved products are thought to clear amyloid plaque.

Jonathan ViolinCEO

Once the antibody gets into the brain and binds the plaque, binding to Fc gamma receptors on local microglia facilitates uptake clearance of these plaques, and that's how we clear plaques and deliver slowing of the cognitive decline at Alzheimer's disease. In contrast to some other entrants in this category, we wanted to make sure that we had very strong phagocytosis. Thirdly, we hypothesized that reducing CDC and ADCC to other effector functions might be responsible for the acute reticulocyte reduction that's seen with trontinemab and could be driving the anemia, as well as potentially improving local tolerability. So, we deployed a handful of clinically validated point mutations, so we're not taking the risk of novel point mutations. Each of these is clinically validated. The combination is novel, so we're not disclosing what those are, but I'll show you in the subsequent slides that we've achieved improved pharmacokinetics.

Jonathan ViolinCEO

We've maintained the phagocytosis of donanemab, and we've spared acute reticulocyte destruction by virtue of this selective effector function modulation. First, why target pyroglutamate forms of amyloid? On this slide, we're showing a modified form of a figure from a Boxer et al. review from a few years ago. We've removed all the small phase I and phase II studies because, unsurprisingly in this space, the clinical results in smaller trials are quite noisy. What's shown here are all the phase III studies, the biggest, best-run studies in this space for every IgG molecule targeting amyloid that's been through a phase III. What you see is a striking correlation between clearance of plaque, as measured by PET tracers on the x-axis, and benefit. So, the CDR Sum of Boxes, a slowing of cognitive decline on the y-axis.

Jonathan ViolinCEO

First, this correlation tells us that clearance of plaque measured by PET tracer is a great biomarker for efficacy. Secondly, we can now start rank ordering which kind of targeting makes the most sense. We've seen some molecules that fail for a variety of reasons in the upper right. Lecanemab, which is approved as Leqembi, in orange in the middle. But numerically at least, the most robust plaque clearing and the numerically best benefit on CDR Sum of Boxes is donanemab, marketed as Kisunla, which again targets the pyroglutamate form of amyloid beta. Lilly's remternetug, which is in phase III now, shows plaque clearance very similar to donanemab. So, we've got another example suggesting that targeting the pyroglutamate form is the most precise way to remove quickly amyloid plaques. Turning then to our own data, first looking at the phagocytic capacity of KRSA-028.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day